US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

58.76

+1.392.43%

Post-market: 58.800.0430+0.07%19:30 EDT

Volume:17.38K

Turnover:1.02M

Market Cap:284.38M

PE:19.22

High:59.14

Open:57.66

Low:57.66

Close:57.37

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.51

T/O Rate:0.36%

Dividend:1.53

Dividend Rate:2.60%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Axsome Therapeutics Schedules Third-Quarter 2026 Financial Results Release and Conference Call

How $950 Million Settlement Will Impact Roivant Sciences Stock (ROIV)

Simply Wall St.

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million

Guardant Health reports COSMOS study published in Cancer Research Communications

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer

Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer

THOMSON REUTERS

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288

THOMSON REUTERS

Missed BrightSpring’s 112% Run? The Argument Behind It Still Holds Curiosity

Simply Wall St.

Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000

Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares

Guardant Health price target raised to $200 from $190 at Guggenheim

BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call

Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer

Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer

New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PTH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":58.757,"timestamp":1791576000000,"preClose":57.3658,"halted":0,"volume":17383,"hourTrading":{"tag":"盘后","latestPrice":58.8,"preClose":58.757,"latestTime":"19:30 EDT","volume":6,"amount":352.2346,"timestamp":1791588604239,"change":0.043,"changeRate":0.000732,"amplitude":0},"delay":0,"changeRate":0.024251383228334613,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Market Closed","change":1.3912,"latestTime":"10-09 16:00:00 EDT","open":57.66,"high":59.1447,"low":57.66,"amount":1021175.720865,"amplitude":0.025881,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":57.3658,"sharesOutstanding":2480000,"nav":57.33757,"aum":287288216.63,"dividendRate":0.02597,"bidAskSpread":0.001697,"preHourTrading":{"tag":"盘前","latestPrice":57.37,"preClose":57.3658,"latestTime":"07:00 EDT","volume":1,"amount":57.37,"timestamp":1791543606921,"change":0.0042,"changeRate":0.000073,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":58.8,"preClose":58.757,"latestTime":"19:30 EDT","volume":6,"amount":352.2346,"timestamp":1791588604239,"change":0.043,"changeRate":0.000732,"amplitude":0},"volumeRatio":0.5106189207267566,"impliedVol":0.2074,"impliedVolPercentile":0.9442},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5106189207267566,"shares":4840000,"dividePrice":1.5259,"high":59.1447,"amplitude":0.025881,"preClose":57.3658,"low":57.66,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":58.757,"eps":3.057033,"divideRate":0.02597,"volume":17383,"delay":0,"ttmEps":3.057033,"open":57.66,"prevYearClose":49.701,"prevWeekClose":60.2082,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":60.2082,"twentyDayClose":60.7692,"sixtyDayClose":58.2191},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673182850","title":"Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2673182850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673182850?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:30","pubTimestamp":1791376200,"startTime":"0","endTime":"0","summary":"Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376463/0/en/propanc-biopharma-reports-data-showing-90-tumor-growth-inhibition-with-prp-in-pancreatic-cancer-models-contrasting-profile-with-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","BK4588","IE00BFMHRM44.USD","ONX","LU1983260115.SGD","LU0320765992.SGD","ON","LU0348723411.USD","LU1861219969.SGD","PTH","LU1720051017.SGD","BK4139","IE00BFTCPJ56.SGD","BK4605","LU0124384867.USD","LU1861214812.USD","LU1978683503.SGD","CANC","IE0009354923.USD","BK4585","BBH","LU0889565916.HKD","LU1548497426.USD","IE00B4R5TH58.HKD","ONG","LU1861220033.SGD","BK4512","IE00BJT1NW94.SGD","IE00BD6J9T35.USD","LU1854103824.USD","LU1861215975.USD","LU2360107325.USD","LU2357305700.SGD","LU0724618433.USD","LU1720051108.HKD","LU1854104046.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B2B36J28.USD","IE0002141913.USD","IE00BZ199S13.USD","LU2298322129.HKD","RVMD","IE0009355771.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673097860","title":"Axsome Therapeutics Schedules Third-Quarter 2026 Financial Results Release and Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2673097860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673097860?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:01","pubTimestamp":1791370901,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics schedules third-quarter 2026 financial results release and conference callAxsome Therapeutics schedules third-quarter 2026 financial results release for Nov. 2, 2026, before the US","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL4gHVzj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2324357040.USD","LU2095319765.USD","BK4007","IE00BQXX3F31.USD","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","NDAQ","AXSM","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4505","BK4588","PTH","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","BCDF","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673062023","title":"How $950 Million Settlement Will Impact Roivant Sciences Stock (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062023","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673062023?lang=en_us&edition=fundamental","pubTime":"2026-10-07 09:22","pubTimestamp":1791336149,"startTime":"0","endTime":"0","summary":"Roivant Sciences reported a quiet Q1 2026 but highlighted progress across its inflammation and immunology pipeline, alongside a US$950 million settlement received from Moderna related to lipid nanoparticle litigation.\nThe combination of a large cash infusion from the settlement and advancing brepocitinib programs gives Roivant Sciences added financial and operational flexibility as it manages ongoing R&D and continuing legal action against Pfizer and BioNTech.\nWe will now examine how Roivant...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/how-950-million-settlement-will-impact-roivant-sciences-stoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/how-950-million-settlement-will-impact-roivant-sciences-stoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068758","title":"Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068758","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068758?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:15","pubTimestamp":1791314128,"startTime":"0","endTime":"0","summary":"• Guardant Health shares dropped due to profit-taking after a multi-month rally.\n• Ongoing unprofitability and high valuation multiples triggered intense selling pressure.\n• The company reported $982.02M in annual revenue and a net profit of $-416.28M.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262202416-market-movers-gh-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","GNOM","BK4588","GH","LU0109394709.USD","LU0320765992.SGD","BK4585","GDOC","PTH","BK4551","GNMX","EKG","BK4196","HELX","LU0889565916.HKD","LFSC","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673981051","title":"Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673981051","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673981051?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:15","pubTimestamp":1791292500,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, Oct.  06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375624/0/en/ascendis-to-share-latest-advances-in-hypoparathyroidism-and-achondroplasia-programs-at-asbmr-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD4GTW91.USD","EEA","IE00BJTD4V19.USD","BK4585","BK4588","UTES","EU","BK4208","IE00BD4GTT62.SGD","IE00BD4GTV84.USD","IE00BJTD4N35.SGD","LU2380233275.USD","BK4156","CNP","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673087032","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087032","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087032?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:43","pubTimestamp":1791243789,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $2.93 millionImmunovant CEO and director Eric Venker increased his direct stake to 257,075 shares following CVAR settlement.92,187 shares wer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL8Rvzcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","IMVT","BK4585","ROIV","BK4139","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085570","title":"Guardant Health reports COSMOS study published in Cancer Research Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085570?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:30","pubTimestamp":1791214209,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","FFOX","LU0889565916.HKD","LU0320765992.SGD","GNMX","PTH","GH","BK4196","EKG","BK4551","BK4535","LU0109394709.USD","GDOC","BK4588","HELX","BK4585","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085807","title":"Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085807?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:27","pubTimestamp":1791214069,"startTime":"0","endTime":"0","summary":"Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrencesGuardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5cqdWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4588","LFSC","GNMX","BK4551","LU0320765992.SGD","PTH","BK4535","HELX","BK4585","EKG","GH","FFOX","GNOM","GDOC","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702723","title":"Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:14","pubTimestamp":1791202453,"startTime":"0","endTime":"0","summary":"Revolution Medicines starts Phase 3 trial of RASONQUE-zoldonrasib combo in first-line metastatic RAS G12D pancreatic cancerRevolution Medicines began dosing patients in a global Phase 3 trial testing ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1LgfsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","PTH","LU0889565916.HKD","IDNA","IE0009354923.USD","LU2210149790.SGD","BK4139","IE00BFTCPJ56.SGD","RVMD","CANC","IE00BQXX3F31.USD","BBH","SG9999014039.USD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BCDF","LU2095319765.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","IE00BJT1NW94.SGD","IE00BQXX3C00.GBP","LU0109394709.USD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","NDAQ","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0320765992.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702923","title":"Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702923?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7YHCFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","RVMD","PTH","BBH","IE0009355771.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B4R5TH58.HKD","IDNA","CANC","IE0009354923.USD","IE00BJJMRZ35.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702771","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702771?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374474/18623/en/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","KBWY","BK4218","BK4585","BK4007","GH","ENDO","HELX","GNMX","GDOC","BK4183","LFSC","BK4196","FFOX","LENZ","LU0109394709.USD","PTH","LU0889565916.HKD","BK4535","BK4139","EKG","BK4588","PK","BK4181","BK4539","GNOM","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709483","title":"Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709483?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:11","pubTimestamp":1791195096,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","RVMD","IDNA","PTH","BBH","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B2B36J28.USD","BK4139","IE00BJT1NW94.SGD","IE0009354923.USD","CANC","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672263897","title":"Missed BrightSpring’s 112% Run? The Argument Behind It Still Holds Curiosity","url":"https://stock-news.laohu8.com/highlight/detail?id=2672263897","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672263897?lang=en_us&edition=fundamental","pubTime":"2026-10-03 21:22","pubTimestamp":1791033739,"startTime":"0","endTime":"0","summary":"If you had paused on 2 October 2025, looking at BrightSpring Health Services as analysts argued over margins, regulation, and aging demographics, the choice did not look simple. For BrightSpring Health Services shareholders, the return over the past year was 112.4%, including dividends. That outcome is now fixed. The real question is what early buyers were weighing back then about specialty pharmacy momentum, leverage, and government reimbursement risk before any of the later earnings...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/missed-brightsprings-112-run-the-argument-behind-it-still-ho","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/missed-brightsprings-112-run-the-argument-behind-it-still-ho","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2324357040.USD","BK4196","LU2089984988.USD","LU2468319806.SGD","BTSG","PSCH","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672419217","title":"Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2672419217","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672419217?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:38","pubTimestamp":1790977094,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker disposes of 200,000 common shares worth $7,324,000Roivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares at a weighted-av","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6N8y8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","BK4585","BK4007","BK4588","ROIV","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672476771","title":"Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672476771","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672476771?lang=en_us&edition=fundamental","pubTime":"2026-10-02 06:00","pubTimestamp":1790892038,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Development Officer Alan B. Sandler disposes of USD 1,264,082 in common sharesRevolution Medicines Chief Development Officer Alan B. Sandler exercised stock options for 6,00","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL9BczFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4139","IE0009354923.USD","BBH","LU0889565916.HKD","LU0109394709.USD","PTH","IE00BJJMRZ35.SGD","IDNA","IE00B2B36J28.USD","RVMD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","CANC","IE0009355771.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672520357","title":"Guardant Health price target raised to $200 from $190 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672520357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672520357?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:37","pubTimestamp":1790858259,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its mod...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","EKG","HELX","GNMX","BK4585","FFOX","BK4588","LU0320765992.SGD","LU0889565916.HKD","BK4196","GNOM","PTH","LFSC","BK4551","BK4535","GDOC","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672475403","title":"BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672475403","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672475403?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:05","pubTimestamp":1790856336,"startTime":"0","endTime":"0","summary":"BrightSpring Health updates financial calendar for third-quarter 2026 results release and callBrightSpring Health Services schedules its third-quarter 2026 earnings release for Oct. 30, 2026.Earnings ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLs3mT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","LU2468319806.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","PTH","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","BCDF","SG9999014013.SGD","LU2210149790.SGD","BK4112","IE00BN0W2T93.GBP","BK4585","LU2089984988.USD","PSCH","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2324357040.USD","LU0314104364.USD","BTSG","IE00BQXX3C00.GBP","BK4196","IE00BQXX3F31.USD","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751724","title":"Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751724","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751724?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:32","pubTimestamp":1790854322,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma buys back 46,000,000 shares for US$ 230 million in Dutch auction tender offerArbutus completed a modified Dutch auction tender offer, repurchasing 46,000,000 common shares for cancel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6Zy8XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","ABUS","BK4585","PTH","BK4139","LU2210150020.SGD","BK4112","BK4007","BCDF","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","ROIV","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671093162","title":"Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671093162","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671093162?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:30","pubTimestamp":1790767828,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma repurchases 46,000,000 shares for USD 230 million in modified Dutch auction tender offerArbutus Biopharma expects to repurchase 46,000,000 common shares for cancellation in a modifie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8GWhnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","ABUS","ROIV","BK4139","SG9999014039.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","PTH","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BCDF","BK4007","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671117244","title":"New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2671117244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671117244?lang=en_us&edition=fundamental","pubTime":"2026-09-30 02:43","pubTimestamp":1790707417,"startTime":"0","endTime":"0","summary":"How hot are biotech stocks? One of the bellwethers for the industry, the iShares Biotechnology ETF ($IBB) (left chart), has gained over 24% year to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4585","XBIX","IBB","BK4550","BK4588","BIS","XLK","BIOY","FBT","JHMH","FXH","FDN","PTH","RXL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}